Literature DB >> 31597668

High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Tomas Vaisar1, Jenny E Kanter1, Jake Wimberger1, Angela D Irwin1, John Gauthier2, Emily Wolfson2, Vanessa Bahnam2, I-Hsien Wu2, Hetal Shah2,3, Hillary A Keenan2, Carla J Greenbaum4, George L King2,3, Jay W Heinecke1, Karin E Bornfeldt5,6.   

Abstract

OBJECTIVE: A subset of people with long-standing type 1 diabetes (T1D) appears to be protected from microvascular and macrovascular complications. Previous studies have focused on improved abilities to respond to glucose and its downstream effects as protective mechanisms. It is unclear whether lipoproteins play a role in the vascular health of these people. We therefore determined whether HDL particle concentration, size, function, and/or protein composition associate with protection from vascular complications. RESEARCH DESIGN AND METHODS: We studied two independent cross-sectional cohorts with T1D: the T1D Exchange Living Biobank (n = 47) and the Joslin Medalist Study (n = 100). Some of the subjects had vascular complications, whereas others never exhibited vascular complications, despite an average duration of diabetes in the cohorts of 45 years. We assessed HDL particle size and concentration by calibrated ion mobility analysis, the HDL proteome by targeted mass spectrometry, and HDL function ex vivo by quantifying cholesterol efflux capacity and inhibition of monocyte adhesion to endothelial cells.
RESULTS: In both cohorts, people without vascular complications exhibited significantly higher concentrations of medium-sized HDL particles (M-HDL) independently of total and HDL cholesterol levels. While no consistent differences in HDL functions were observed ex vivo, people without vascular complications had higher levels of HDL-associated paraoxonase 1 (PON1), an enzyme that inhibits atherosclerosis in animal models.
CONCLUSIONS: Elevated concentrations of M-HDL particles and elevated levels of HDL-associated PON1 may contribute to long-term protection from the vascular complications of diabetes by pathways that are independent of total cholesterol and HDL cholesterol.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31597668      PMCID: PMC6925582          DOI: 10.2337/dc19-0772

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  39 in total

1.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

2.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.

Authors:  Brendan MacLean; Daniela M Tomazela; Nicholas Shulman; Matthew Chambers; Gregory L Finney; Barbara Frewen; Randall Kern; David L Tabb; Daniel C Liebler; Michael J MacCoss
Journal:  Bioinformatics       Date:  2010-02-09       Impact factor: 6.937

3.  Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine.

Authors:  Mira Rosenblat; Jacob Vaya; Diana Shih; Michael Aviram
Journal:  Atherosclerosis       Date:  2004-12-29       Impact factor: 5.162

4.  Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults.

Authors:  M M Bergmann; T Byers; D S Freedman; A Mokdad
Journal:  Am J Epidemiol       Date:  1998-05-15       Impact factor: 4.897

5.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

6.  ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL.

Authors:  Ashley M Vaughan; John F Oram
Journal:  J Lipid Res       Date:  2006-08-10       Impact factor: 5.922

7.  Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Olga V Demler; Steven J Adelman; Heidi L Collins; Robert J Glynn; Paul M Ridker; Daniel J Rader; Samia Mora
Journal:  Circulation       Date:  2017-04-27       Impact factor: 29.690

Review 8.  Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion.

Authors:  Michael Aviram; Jacob Vaya
Journal:  Curr Opin Lipidol       Date:  2013-08       Impact factor: 4.776

9.  Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1).

Authors:  Denis Josse; Christine Ebel; David Stroebel; Alice Fontaine; Frédéric Borges; Aude Echalier; Delphine Baud; Frédérique Renault; Marc Le Maire; Eric Chabrieres; Patrick Masson
Journal:  J Biol Chem       Date:  2002-06-21       Impact factor: 5.157

10.  Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.

Authors:  John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

View more
  12 in total

1.  Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice.

Authors:  Tatjana Josefs; Debapriya Basu; Tomas Vaisar; Britt Arets; Jenny E Kanter; Lesley-Ann Huggins; Yunying Hu; Jianhua Liu; Noemie Clouet-Foraison; Jay W Heinecke; Karin E Bornfeldt; Ira J Goldberg; Edward A Fisher
Journal:  Circ Res       Date:  2021-02-03       Impact factor: 17.367

2.  Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes.

Authors:  Jingyi Hu; Zhiwen Liu; Yue Tong; Zubing Mei; Aimin Xu; Pengcheng Zhou; Xiaoyan Chen; Weili Tang; Zhiguang Zhou; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-22       Impact factor: 5.555

Review 3.  OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention.

Authors:  Stephen J Peterson; Abu Choudhary; Amardeep K Kalsi; Shuyang Zhao; Ragin Alex; Nader G Abraham
Journal:  Diagnostics (Basel)       Date:  2020-11-20

Review 4.  High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma.

Authors:  Vasily A Kudinov; Olga Yu Alekseeva; Tatiana I Torkhovskaya; Konstantin K Baskaev; Rafael I Artyushev; Irina N Saburina; Sergey S Markin
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

5.  Clinical Characteristics, Residual Beta-Cell Function and Pancreatic Auto-Antibodies in Thai people with Long-Standing Type 1 Diabetes Mellitus.

Authors:  Yotsapon Thewjitcharoen; Sirinate Krittiyawong; Somboon Vongterapak; Soontaree Nakasatien; Suphab Aroonparkmongkol; Ishant Khurana; Assam El-Osta; Thep Himathongkam
Journal:  J ASEAN Fed Endocr Soc       Date:  2020-08-03

Review 6.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

7.  Lipid analysis by ion mobility spectrometry combined with mass spectrometry: A brief update with a perspective on applications in the clinical laboratory.

Authors:  Joshua A Dubland
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-12-13

8.  The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients.

Authors:  Philip W Connelly; Andrew T Yan; Michelle M Nash; Rachel M Wald; Charmaine Lok; Lakshman Gunaratnam; Anish Kirpalani; G V Ramesh Prasad
Journal:  Front Cardiovasc Med       Date:  2021-12-02

9.  Short-Term Acyl-CoA:Cholesterol Acyltransferase Inhibition, Combined with Apoprotein A1 Overexpression, Promotes Atherosclerosis Inflammation Resolution in Mice.

Authors:  Jaume Amengual; Yoscar Ogando; Cyrus Nikain; Alexandra Quezada; Kun Qian; Tomas Vaisar; Edward A Fisher
Journal:  Mol Pharmacol       Date:  2020-12-31       Impact factor: 4.436

10.  Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.

Authors:  Antonio J Amor; Esmeralda Castelblanco; Marta Hernández; Marga Gimenez; Minerva Granado-Casas; Jesús Blanco; Berta Soldevila; Enric Esmatjes; Ignacio Conget; Nuria Alonso; Emilio Ortega; Didac Mauricio
Journal:  Cardiovasc Diabetol       Date:  2020-08-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.